Gene "CYP2C8"
Found 2 records
Gene information
Gene symbol:
CYP2C8
See related:
Ensembl: ENSG00000138115, Gene ID: 1558
Additive variants :
Undetected
Genetic interaction partners
No data
Modifier statisitcs
Record:
2 
Disorder:
1 
Vriant:
2 
Reference:
1 
Effect type:
Expressivity(2)  
Modifier effect:
Risk factor(2)  
Details：
  • Variant 1:
    CYP2C8:c.206G>A(p.Arg139Lys)
    Gene:
    CYP2C8
    Genomic location:
    chr10:96827030
    dbSNP ID:
    rs11572080
    Target disease:
    Colorectal Cancer(DOID_9256)
    Effect type:
    Expressivity 
    Modifier effect:
    Risk factor 
    Evidence:
    OR=0.73, 95% CI: (0.56, 0.95) 
    Effect:
    The reduction in risk of colorectal cancer with regular NSAID use
    Reference:
    PMID16141797
    Title:
    No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma.
    Species studied:
    Human
    Abstract:
    Regular continuous non-steroidal anti-inflammatory drug (NSAID) use has been associated with a reduction in risk of colorectal cancer. Our objective was to investigate whether or not a number of the polymorphic genes involved in the metabolism of NSAIDs, including cytochrome P450 s (CYPs), act as modifiers of this protective effect.
  • Variant 2:
    CYP2C8:c.1196A>G(p.Lys399Arg)
    Gene:
    CYP2C8
    Genomic location:
    chr10:96798749
    dbSNP ID:
    rs10509681
    Target disease:
    Colorectal Cancer(DOID_9256)
    Effect type:
    Expressivity 
    Modifier effect:
    Risk factor 
    Evidence:
    OR=0.73, 95% CI: (0.56, 0.95) 
    Effect:
    The reduction in risk of colorectal cancer with regular NSAID use
    Reference:
    PMID16141797
    Title:
    No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma.
    Species studied:
    Human
    Abstract:
    Regular continuous non-steroidal anti-inflammatory drug (NSAID) use has been associated with a reduction in risk of colorectal cancer. Our objective was to investigate whether or not a number of the polymorphic genes involved in the metabolism of NSAIDs, including cytochrome P450 s (CYPs), act as modifiers of this protective effect.